Prediction of coronary heart disease using risk factor categories.

BACKGROUND The objective of this study was to examine the association of Joint National Committee (JNC-V) blood pressure and National Cholesterol Education Program (NCEP) cholesterol categories with coronary heart disease (CHD) risk, to incorporate them into coronary prediction algorithms, and to compare the discrimination properties of this approach with other noncategorical prediction functions. METHODS AND RESULTS This work was designed as a prospective, single-center study in the setting of a community-based cohort. The patients were 2489 men and 2856 women 30 to 74 years old at baseline with 12 years of follow-up. During the 12 years of follow-up, a total of 383 men and 227 women developed CHD, which was significantly associated with categories of blood pressure, total cholesterol, LDL cholesterol, and HDL cholesterol (all P<.001). Sex-specific prediction equations were formulated to predict CHD risk according to age, diabetes, smoking, JNC-V blood pressure categories, and NCEP total cholesterol and LDL cholesterol categories. The accuracy of this categorical approach was found to be comparable to CHD prediction when the continuous variables themselves were used. After adjustment for other factors, approximately 28% of CHD events in men and 29% in women were attributable to blood pressure levels that exceeded high normal (> or =130/85). The corresponding multivariable-adjusted attributable risk percent associated with elevated total cholesterol (> or =200 mg/dL) was 27% in men and 34% in women. CONCLUSIONS Recommended guidelines of blood pressure, total cholesterol, and LDL cholesterol effectively predict CHD risk in a middle-aged white population sample. A simple coronary disease prediction algorithm was developed using categorical variables, which allows physicians to predict multivariate CHD risk in patients without overt CHD.

[1]  B. Brodie,et al.  A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. , 1952, The Journal of biological chemistry.

[2]  T E Walsh,et al.  Reporting results. , 1969, Archives of otolaryngology.

[3]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[4]  W. Kannel,et al.  Differences in coronary heart disease in Framingham, Honolulu and Puerto Rico. , 1974, Journal of chronic diseases.

[5]  Michael H. Kutner Applied Linear Statistical Models , 1974 .

[6]  R. Brand,et al.  Multivariate Prediction of Coronary Heart Disease in the Western Collaborative Group Study Compared to the Findings of the Framingham Study , 1976, Circulation.

[7]  W. Haskell,et al.  The distribution of plasma lipoproteins in middle-aged male runners. , 1976, Metabolism: clinical and experimental.

[8]  Statistical design considerations in the NHLI multiple risk factor intervention trial (MRFIT). The Multiple Risk Factor Intervention Trial Group. , 1977, Journal of Chronic Diseases.

[9]  W. Kannel,et al.  Diabetes, blood lipids, and the role of obesity in coronary heart disease risk for women. The Framingham study. , 1977, Annals of internal medicine.

[10]  W. Kannel,et al.  An investigation of coronary heart disease in families. The Framingham offspring study. , 1979, American journal of epidemiology.

[11]  D L McGee,et al.  Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study , 1979, Diabetes Care.

[12]  W. Kannel,et al.  Multiple risk functions for predicting coronary heart disease: the concept, accuracy, and application. , 1982, American heart journal.

[13]  E. Barrett-Connor,et al.  Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-Up Study. , 1983, JAMA.

[14]  Pasley Bh,et al.  Prescribing estrogen during menopause: physician survey of practices in 1974 and 1981. , 1984 .

[15]  B. Pasley,et al.  Prescribing estrogen during menopause: physician survey of practices in 1974 and 1981. , 1984, Public health reports (1974).

[16]  P. Wilson,et al.  Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. , 1985, The New England journal of medicine.

[17]  C. Caspersen,et al.  Physical activity and the incidence of coronary heart disease. , 1987, Annual review of public health.

[18]  P. Wilson,et al.  Coronary risk prediction in adults (the Framingham Heart Study) , 1987, The American journal of cardiology.

[19]  W. Kannel,et al.  Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study. , 1987, Journal of chronic diseases.

[20]  K. Anderson,et al.  Longitudinal and secular trends in lipoprotein cholesterol measurements in a general population sample. The Framingham Offspring Study. , 1987, Atherosclerosis.

[21]  D H Blankenhorn,et al.  Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. , 1987, JAMA.

[22]  R. D'Agostino,et al.  Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.

[23]  P. Wilson,et al.  Leisure time physical activity in the Framingham Offspring Study. Description, seasonal variation, and risk factor correlates. , 1989, American journal of epidemiology.

[24]  D. Reed,et al.  Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly? , 1990, JAMA.

[25]  W. Raub From the National Institutes of Health. , 1990, JAMA.

[26]  W. Kannel,et al.  Parental history is an independent risk factor for coronary artery disease: the Framingham Study. , 1990, American heart journal.

[27]  P. Wilson,et al.  High-density lipoprotein, low-density lipoprotein and coronary artery disease. , 1990, The American journal of cardiology.

[28]  G A Colditz,et al.  A meta-analysis of physical activity in the prevention of coronary heart disease. , 1990, American journal of epidemiology.

[29]  R. D'Agostino,et al.  Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. , 1990, American heart journal.

[30]  P. Wilson,et al.  Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. , 1990, Clinical chemistry.

[31]  R. Paffenbarger,et al.  Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. , 1991, The New England journal of medicine.

[32]  K. Anderson,et al.  An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.

[33]  G A Colditz,et al.  Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. , 2004, Preventive medicine.

[34]  Estrogen and coronary heart disease in women. , 1991 .

[35]  K. Anderson,et al.  Cardiovascular disease risk profiles. , 1991, American heart journal.

[36]  E. Barrett-Connor,et al.  Estrogen and coronary heart disease in women , 1991, JAMA.

[37]  J. Manson,et al.  Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. , 1991, The New England journal of medicine.

[38]  National Education Programs Working Group report on the management of patients with hypertension and high blood cholesterol. , 1991, Annals of Internal Medicine.

[39]  Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. , 1991 .

[40]  G. Colditz,et al.  Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence☆☆☆ , 1991 .

[41]  G. Myers,et al.  Blood lipid measurements: Variations and practical utility , 1992, Journal of the American Medical Association (JAMA).

[42]  M. Abrahamowicz,et al.  The benefits of treating hyperlipidemia to prevent coronary heart disease. Estimating changes in life expectancy and morbidity. , 1992, JAMA.

[43]  Blood lipid measurements: Variations and practical utility , 1992, JAMA.

[44]  The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) , 1993, Archives of internal medicine.

[45]  E. Ernst,et al.  Fibrinogen as a Cardiovascular Risk Factor , 1993, Annals of Internal Medicine.

[46]  W. Kannel,et al.  Hypercholesterolemia and Coronary Risk in the Elderly: The Framingham Study. , 1993, The American journal of geriatric cardiology.

[47]  Donald A. Smith Fibrinogen as a cardiovascular risk factor: a meta-analysis , 1993, ACP Journal Club.

[48]  F. Kummerow,et al.  Viewpoint on the Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. , 1993, Journal of the American College of Nutrition.

[49]  J. Mckenney,et al.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.

[50]  Bruce Kinosian,et al.  Cholesterol and Coronary Heart Disease: Predicting Risks by Levels and Ratios , 1994, Annals of Internal Medicine.

[51]  P. Wood Physical activity, diet, and health: independent and interactive effects. , 1994, Medicine & Science in Sports & Exercise.

[52]  Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[53]  Diana B. Petitti,et al.  Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in Medicine , 1994 .

[54]  L. Wilkins National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). , 1994 .

[55]  L. Wilkins,et al.  National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). , 1994, Circulation.

[56]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[57]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[58]  K. Yano,et al.  Distribution and correlates of insulin in elderly men. The Honolulu Heart Program. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[59]  R S Paffenbarger,et al.  Exercise intensity and longevity in men. The Harvard Alumni Health Study. , 1995, JAMA.

[60]  F. Galetta,et al.  [Fibrinogen as a cardiovascular risk factor]. , 1995, Minerva cardioangiologica.

[61]  D. Levy Have expert panel guidelines kept pace with new concepts in hypertension? , 1995, The Lancet.

[62]  L. Coupal,et al.  Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? , 1995, JAMA.

[63]  Cholesterol screening. Once is not enough. , 1995, Archives of internal medicine.

[64]  R. Glynn,et al.  HDL cholesterol predicts coronary heart disease mortality in older persons. , 1995, JAMA.

[65]  U. Goldbourt,et al.  Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study. , 1995, Journal of clinical epidemiology.

[66]  C. A. Ferguson,et al.  Immunoseparation method for measuring low-density lipoprotein cholesterol directly from serum evaluated. , 1995, Clinical chemistry.

[67]  T. Lancet,et al.  West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996, The Lancet.

[68]  P. Macfarlane,et al.  West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .

[69]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[70]  A. Folsom,et al.  Recent trends in acute coronary heart disease--mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. , 1996, The New England journal of medicine.

[71]  L. Ramsay,et al.  Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table , 1996, The Lancet.

[72]  Ames,et al.  PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .

[73]  D.,et al.  Regression Models and Life-Tables , 2022 .